Core Viewpoint - Lepu Medical (300003.SZ) announced that its subsidiary, Shanghai Minwei Biotech, has granted a paid license for its proprietary MWN105 injection to Danish company Sidera, which will have exclusive rights to develop and commercialize the product outside of Greater China [1] Group 1 - Shanghai Minwei Biotech will receive a 9.99% equity stake in Sidera as part of the licensing agreement [1] - The initial investment and recent milestone payments from Sidera to Shanghai Minwei Biotech will total $35 million [1] - Sidera is obligated to pay up to $1.01 billion in milestone payments based on clinical development and commercialization sales [1] Group 2 - Shanghai Minwei Biotech has the right to receive a tiered sales commission from Sidera based on actual annual net sales, excluding Greater China [1]

Core Viewpoint - Lepu Medical (300003.SZ) announced that its subsidiary, Shanghai Minwei Biotech, has granted a paid license for the MWN105 injection to Danish company Sidera, which will have exclusive rights to develop and commercialize the product outside of Greater China [1] Group 1: Licensing Agreement - Shanghai Minwei Biotech will receive a 9.99% equity stake in Sidera as part of the licensing agreement [1] - The initial investment and recent milestone payments from Sidera to Shanghai Minwei Biotech will total $35 million [1] - Sidera will pay up to $1.01 billion in milestone payments based on clinical development and commercialization sales [1] Group 2: Revenue Sharing - Shanghai Minwei Biotech has the right to receive a tiered sales commission from Sidera based on actual annual net sales, excluding Greater China [1]

Core Viewpoint - Lepu Medical announced an adjustment to the conversion price of its bonds, increasing from RMB 27.63 per share to RMB 27.86 per share, effective from November 3, 2025 [1] Group 1 - The bond is referred to as Lepu Convertible Bond 2 [1] - The adjustment in the conversion price reflects a change in the company's financial strategy [1]

Group 1 - The core point of the article is that Lepu Medical has licensed its MWN105 injection to Danish company Sidera, granting Sidera exclusive rights to develop and commercialize the product globally, excluding Greater China [1] - Lepu Medical's subsidiary, Shanghai Minwei Biotech, will receive a 9.99% equity stake in Sidera as part of the licensing deal [1] - The initial investment and recent milestone payments from Sidera to Shanghai Minwei Biotech will total $35 million, with potential milestone payments reaching up to $1.01 billion based on clinical development and commercialization sales [1] Group 2 - The agreement is expected to enhance the global positioning of GLP-1 multi-target drugs, which are gaining traction in the fields of diabetes, obesity, and metabolic diseases [2] - The collaboration aims to expand overseas markets, providing new treatment options for patients while increasing the company's brand influence and international competitiveness [2] - The company emphasizes a dual approach of independent research and open collaboration to accelerate the clinical transformation and market coverage of GLP-1 multi-target drugs, integrating into the global drug innovation ecosystem [2]

Core Insights - Lepu Medical announced a licensing agreement for its MWN105 injection with Denmark's SideraBioAps, granting exclusive rights for development and commercialization outside Greater China [1] - The initial payment and recent milestone payments total $35 million, with SideraBioAps acquiring a 9.99% equity stake in Shanghai Minwei Biotechnology [1] - SideraBioAps is set to pay up to $1.01 billion in milestone payments based on clinical development and commercialization sales [1]

Core Viewpoint - Lepu Medical (300003) announced the licensing of its proprietary MWN105 injection to Denmark's Sidera Bio Aps, granting exclusive rights for development and commercialization outside Greater China [1] Group 1: Licensing Agreement - Lepu Medical's subsidiary, Shanghai Minwei Biotechnology Co., Ltd., will license MWN105 injection to Sidera Bio Aps for a fee [1] - Sidera Bio Aps will receive exclusive rights to develop and commercialize MWN105 injection globally, excluding Greater China [1] Group 2: Financial Aspects - As part of the licensing deal, Shanghai Minwei Biotechnology will acquire a 9.99% equity stake in Sidera Bio Aps [1] - The agreement includes receiving licensing fees from Sidera Bio Aps for the MWN105 injection [1]

Core Viewpoint - Lepu Medical (300003.SZ) has signed an agreement with Denmark's Sidera for the global development and commercialization rights of MWN105 injection, a triple agonist for GLP-1/GIP/FGF21, excluding Greater China [1] Group 1 - Shanghai Minwei Bio will receive a 9.99% equity stake in Sidera as part of the agreement [1] - The company is entitled to receive milestone payments totaling up to $1.01 billion [1] - Shanghai Minwei Bio will also earn sales commissions from Sidera [1] Group 2 - This agreement is expected to enhance the global positioning of the company's GLP-1 multi-target drugs and improve international competitiveness [1] - There are uncertainties associated with drug development and market launch, as well as the milestone payment amounts [1]

证券代码：300003 证券简称：乐普医疗 公告编号：2025-103 乐普（北京）医疗器械股份有限公司 关于子公司与Sidera Bio Aps.签署授权许可协议暨 对外投资的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 重要内容提示： 乐普（北京）医疗器械股份有限公司（以下简称"公司"）旗下控股子公司上 海民为生物技术有限公司（以下简称"上海民为生物"）将具有自主知识产权的 MWN105注射液（以下简称"许可产品"）有偿许可给丹麦Sidera Bio Aps.（以下 简称"丹麦Sidera"），丹麦Sidera公司将获得在除大中华区（中国大陆、香港特 别行政区、澳门特别行政区及台湾地区）以外的全球范围（以下简称"许可范围"） 内开发和商业化的独家权利。作为对外许可交易对价一部分，上海民为生物将取得 丹麦Sidera公司9.99%的股权，且将从丹麦Sidera获得MWN105注射液授权许可费。 一、交易事项概述 公司控股子公司上海民为生物将具有自主知识产权的MWN105注射液有偿许 可给丹麦Sidera，丹麦Sidera公司将获得在除大中华区（中国大 ...

证券代码：300003 证券简称：乐普医疗 公告编号：2025-102 债券代码：123108 债券简称：乐普转 2 乐普（北京）医疗器械股份有限公司 关于可转债乐普转 2 转股价格调整的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 一、关于可转换公司债券转股价格调整的有关规定 乐普（北京）医疗器械股份有限公司（以下简称：公司）经中国证券监督管 理委员会出具的《关于同意乐普（北京）医疗器械股份有限公司向不特定对象发 行可转换公司债券注册的批复》（证监许可〔2021〕741号）核准，于2021年3 月30日向不特定对象发行了1,638.00万张可转换公司债券（以下简称"可转债"）， 每张面值100元，发行总额163,800.00万元。 根据《乐普（北京）医疗器械股份有限公司创业板向不特定对象发行可转换 公司债券募集说明书》（以下简称"《募集说明书》"）发行条款以及中国证券 监督管理委员会（以下简称"中国证监会"）关于可转换公司债券发行的有关规 定，"乐普转2"在本次发行之后，当公司因送红股、转增股本、增发新股、配 股或派发现金股利等情况（ ...

证券代码：300003 证券简称：乐普医疗 公告编号：2025-101 乐普（北京）医疗器械股份有限公司 关于回购股份注销完成暨持股 5%以上股东持股比例 变动触及 1%整数倍的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、公司本次注销回购股份37,215,700股，占公司截至2025年10月28日总股 本1,880,612,067股的比例为1.9789%，实际注销金额608,422,944元。本次注销 完成后，公司总股本将减少37,215,700股。 2、经中国证券登记结算有限责任公司深圳分公司审核确认，公司本次 37,215,700股回购股份注销事宜已于2025年10月30日办理完成。 3、本次回购股份注销完成后，公司股东中国船舶重工集团公司第七二五研 究所（洛阳船舶材料研究所）持有公司的股份数量不变的情况下，持有公司股份 比例由12.98%被动增加至13.24%，权益变动被动触及1%的整数倍。本次权益 变动不会导致公司控股股东及实际控制人发生变化。 一、回购股份的实施情况 （一）2021年回购股份计划的实施情况 公司于2021 ...